Patent: 7,932,267
✉ Email this page to a colleague
Summary for Patent: 7,932,267
Title: | Use of .alpha.-glucosidase inhibitors to treat alphavirus infections |
Abstract: | The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound .alpha.-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an .alpha.-glucosidase inhibitor and at least one additional therapeutic agent. |
Inventor(s): | Blatt; Lawrence M. (San Francisco, CA), Tan; Hua (Daly City, CA), Seiwert; Scott (Pacifica, CA) |
Assignee: | Intermune, Inc. (Brisbane, CA) |
Application Number: | 12/617,676 |
Patent Claims: | see list of patent claims |
Details for Patent 7,932,267
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Kadmon Pharmaceuticals Llc | INFERGEN | interferon alfacon-1 | Injection | 103663 | 10/06/1997 | ⤷ Try a Trial | 2025-03-08 |
Horizon Therapeutics Ireland Dac | ACTIMMUNE | interferon gamma-1b | Injection | 103836 | 02/25/1999 | ⤷ Try a Trial | 2025-03-08 |
Merck Sharp & Dohme Corp. | PEGINTRON | peginterferon alfa-2b | Injection | 103949 | 01/19/2001 | ⤷ Try a Trial | 2025-03-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |